First Trust Morningstar Dividend Leaders ETF Exposes 5.5% to Merck’s AI Drug Discovery Pact
First Trust Morningstar Dividend Leaders ETF allocates 5.48% of its portfolio to Merck, which launched a strategic AI drug discovery collaboration with Mayo Clinic targeting multiple sclerosis and inflammatory diseases. Merck shares trade 6.1% above their 20-day moving average and near 52-week highs, boosting ETF momentum, pressuring its value profile.
1. Portfolio Exposure
First Trust Morningstar Dividend Leaders ETF holds 5.48% of its assets in Merck, making it one of the fund’s largest positions. This concentration amplifies the impact of Merck’s stock moves on the ETF’s performance and risk profile.
2. Merck-Mayo AI Collaboration
Merck has entered a strategic partnership with Mayo Clinic to leverage AI and extensive multimodal clinical data for drug discovery, focusing initially on inflammatory bowel disease, atopic dermatitis and multiple sclerosis. This marks the first major biopharma tie-up for Mayo Clinic at this scale.
3. Technical Momentum and Valuation
Merck shares are trading 6.1% above their 20-day simple moving average and are approaching 52-week highs, underscoring strong bullish momentum. However, the stock’s low relative value score suggests it is priced at a premium, which could weigh on the ETF’s valuation metrics.